XPO1 and cancer: Pathway analysis revealed that selinexor-treated CF365 tumors had upregulation of the β-catenin degradation pathway, modulated WNT signaling and androgen receptor signaling, which is in line with the known effects of XPO1 inhibition in cancer cells (42) (Figure 5A, top panels).